Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MONSANTO MOVING CHARLES FADEN TO SEARLE MANAGEMENT TEAM

Executive Summary

MONSANTO MOVING CHARLES FADEN TO SEARLE MANAGEMENT TEAM as exec VP of the pharmaceutical company, Monsanto said in a Jan. 27 press release. As corporate VP and general manager of Monsanto's health care division, Faden played a key role in the search for Searle and Monsanto's integration of the company since the acquisition last summer. In his new position, Faden will report to Searle President O. B. Parrish, and will serve on Searle's exec cmte. with responsibility for internatl. regional operations in Asia, Canada, and Latin America. He will also be in charge of market development and technical operations. Faden is a former Squibb pharmaceutical president. Former Searle President and DEO John Robson is leaving the company on Jan. 31, and a three-man management team consisting of Parrish, Faden and Searle board Chairman Earle Harbison will be in charge of operations. Parrish, formerly president of Searle's pharmaceutical group, is the key holdover from previous management in the new Monsanto drug group. In a separate announcement, Monsanto said that Harbison has been elected Vice Chairman of the Monsanto board. Searle, operating as a wholly owned Monsanto subsidiary since October, now includes the Searle marketing and R&D units as well as Monsanto's U.S. and internatl. health care business and life sciences research and development program. Searle plans to spend between $160-$170 mil. in 1986 on R&D after a recent consolidation of the Searle and Monsanto life sciences research Monsanto is also realigning its top corporate management positions. In a Jan. 24 press release, the chemical company said that CEO Richard Mahoney will become chairman, replacing Louis Fernandez who is taking early retirement. The change is effective April 1. Exec VP and President of Monsanto Chemical Co. Francis Fitzgerald was named chief operating officer and a member of the Monsanto board. Fitzgerald was recently cited by a Fortune survey of headhunters as a prime chief exec candidate for other firms.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS009633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel